Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.06.
A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Morgan Stanley set a $5.30 target price on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th.
Check Out Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter in the prior year, the business posted ($0.41) EPS. On average, research analysts predict that Recursion Pharmaceuticals will post -0.94 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This represents a 1.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total value of $100,200.00. Following the completion of the sale, the director owned 6,158,287 shares of the company’s stock, valued at approximately $20,568,678.58. This trade represents a 0.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,408 shares of company stock valued at $434,976 in the last three months. Insiders own 6.65% of the company’s stock.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of large investors have recently modified their holdings of the business. MCF Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter worth approximately $27,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $41,000. Fund Advisors of America Inc FL purchased a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at $45,000. Integral Investment Advisors Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $39,000. Finally, MQS Management LLC purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth $41,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.
The company develops therapies for areas including oncology, rare diseases, and neurological disorders.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
